We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Also in today’s newsletter, the latest tech sector lay-offs
Linklaters, The Bank of England and JPMorgan Chase are making virtual and on-site psychologists available
Evidence of the catastrophic effects of increased screen-time is now overwhelming
Occupational therapists may provide one practical solution to those struggling with their physical or mental health
Money problems experienced by elderly customers can be red flags for families and institutions alike
Investment in psychological support fails to keep pace with rising demand, with acute delays for eating disorder sufferers
Tech start-ups are building artificial intelligence-powered tools for employee wellbeing
For all its landmark status, lecanemab may end up representing a triumph of hope over evidence
Other countries have found big answers to managing ageing populations and it’s time Britain did, too
Parental anxiety is contagious but we constantly push for our children’s successes and intervene in their failures
Committees cite inappropriate collaboration between FDA and drugmaker
I was tethered to my partner when we fell 200m, beginning an almost unbelievable new chapter in my life
While employment has become less physically dangerous, it seems to have become more psychologically harmful
Eric Adams’s plan may not be perfect, but we desperately need a better system for aiding people who are mentally ill
New research shows work-related stress and health issues are rising, but flexibility and support from managers can help
Lars Lannfelt had a key role in developing a drug that has shown some promise in tackling Alzheimer’s
Dementia drug development, diagnostics and delivery still require much more investment
At what point does bargain hunting turn into shopping addiction?
Japanese company refuses to rule out possibility treatment contributed to brain bleeds
Shares fall 11% following two patient deaths in trials of lecanemab
The early death of an Alzheimer’s patient taking part in lecanemab trials sent shares down
Working-age people withdrawing from the workforce entirely raises concerns
We need to invest in the tools that enable people to stay well in work and prevent our workers from reaching crisis point
Culture and engagement are key to healthier staff
FT/Vitality survey finds evidence of a workforce in poor shape
International Edition
